NCT04137224 - Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2019

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions

Diffuse Cutaneous Systemic Sclerosis

Interventions

BIOLOGICAL

IgPro20

Human normal immunoglobulin for subcutaneous administration

BIOLOGICAL

IgPro10

Human normal immunoglobulin for intravenous administration

Trial Locations (9)

Royal Adelaide Hospital, Adelaide

Charité Universitätsmedizin Berlin, Berlin

Azienda Ospedaliera Gaetano Pini, Milan

ASST Spedali Civili di Brescia, Brescia

Uniklinik Köln, innere Medizin, Cologne

Uniwersytecki Szpital Kliniczny W Bialymstoku, Bialystok

Szpital Kliniczny Jezus, Warsaw

Narodowy Instytut Geriatrii, Warsaw

The Royal Free Hospital, London